S
Steven R. Deitcher
Researcher at Cleveland Clinic
Publications - 79
Citations - 4273
Steven R. Deitcher is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Venous thrombosis & Vincristine. The author has an hindex of 28, co-authored 79 publications receiving 3984 citations. Previous affiliations of Steven R. Deitcher include University of Tennessee Health Science Center & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Paul M. Ridker,Samuel Z. Goldhaber,Ellie Danielson,Yves Rosenberg,Charles S. Eby,Steven R. Deitcher,Mary Cushman,Stephan Moll,Craig M. Kessler,C. Gregory Elliott,Rolf Paulson,Turnly Wong,Kenneth A. Bauer,Bruce A. Schwartz,Joseph P. Miletich,Henri Bounameaux,Robert J. Glynn +16 more
TL;DR: Long-term, low-intensity warfarin therapy is a highly effective method of preventing recurrent venous thromboembolism.
Journal ArticleDOI
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Steven R. Deitcher,Craig M. Kessler,Geno J. Merli,James R. Rigas,Roger M. Lyons,Jawed Fareed +5 more
TL;DR: Enoxaparin treatment was feasible, generally well tolerated, and effective for a 180-day period in the secondary prevention of venous thromboembolic events in patients with active malignancy.
Journal ArticleDOI
Marqibo ® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
TL;DR: VSLI was developed to increase the circulation time, optimize delivery to target tissues and facilitate dose intensification without increasing toxicity, and in xenograft studies in mice, VSLI had a higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug totarget tissues compared to standard VCR.
Journal ArticleDOI
Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review
Marcelo Gomes,Steven R. Deitcher +1 more
TL;DR: For example, the authors found that third-generation progestins (desogestrel or gestodene) seem to be associated with higher risk of venous thromboembolic events.
Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy
Marcelo Gomes,Steven R. Deitcher +1 more
TL;DR: The indication of a lower or a lack of VTE risk associated with the use of progestin-only contraceptives and with transdermal HRT suggests that these therapies may be safer than combination oral contraceptive pills and oral HRT for women in whom oral estrogen therapy is considered contraindicated.